Cargando…
Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit?
BACKGROUND: Neoadjuvant therapies (neoTx) have revolutionized the treatment of borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PCa) by significantly increasing the rate of R0 resections, which remains the only curative strategy for these patients. However, there is still room...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541356/ https://www.ncbi.nlm.nih.gov/pubmed/32776259 http://dx.doi.org/10.1007/s00423-020-01946-4 |